Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Editas Medicine Raises USD120 Million in Series B Financing 13
Editas Medicine Raises US$43 Million In Series A Financing 16
Partnerships 18
Editas Medicine Enters into Licensing and Option Agreement with Beam Therapeutics 18
Allergan and Editas Medicine Exercise of Options to Co-Develop EDIT-101 19
Adverum Biotechnologies Extends Agreement with Editas Medicine 20
Editas Medicine Enters into Agreement with Fondazione Telethon and Ospedale San Raffaele 21
Editas Medicine Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 22
Juno Therapeutics Enters into Research Agreement with Editas Medicine 23
Licensing Agreements 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 26
Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 28
Editas Medicine Enters into Licensing Agreement with Duke University 29
Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 30
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 31
Equity Offering 33
Editas Medicine Plans to Raise Funds through Public Offering of Securities 33
Editas Medicine Plans to Raise up to USD150 Million in Public Offering of Shares 34
Editas Medicine Raises USD57.5 Million in Public Offering of Shares 35
Editas Medicine Raises USD103.5 Million in Public Offering of Shares 37
Editas Medicine Raises USD108.6 Million in IPO 39
Editas Medicine Inc – Key Competitors 41
Editas Medicine Inc – Key Employees 42
Editas Medicine Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Nov 07, 2018: Editas Medicine announces third quarter 2018 results and update 44
Aug 06, 2018: Editas Medicine announces second quarter 2018 results and update 46
May 03, 2018: Editas Medicine Announces First Quarter 2018 Results and Update 48
Mar 06, 2018: Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update 50
Nov 07, 2017: Editas Medicine Announces Third Quarter 2017 Results and Update 52
Aug 09, 2017: Editas Medicine Announces Second Quarter 2017 Results and Update 54
May 15, 2017: Editas Medicine Announces First Quarter 2017 Results and Update 56
Mar 07, 2017: Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update 58
Corporate Communications 60
Oct 01, 2018: Editas Medicine Grows Scientific Leadership with two new appointments 60
Mar 28, 2018: Editas Medicine Appoints James C. Mullen As Board Chairman 61
Feb 16, 2018: Editas Medicine Appoints Jessica Hopfield, Ph.D., As Board Director 62
May 31, 2017: Editas Medicine Names Andrew Hirsch to Board of Directors 63
Mar 03, 2017: Editas Medicine Announces Departure of Chief Operating Officer 64
Government and Public Interest 65
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 65
Product News 66
12/11/2017: Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia 66
May 13, 2017: Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas 67
Clinical Trials 68
May 11, 2017: Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia 68
Other Significant Developments 69
Jan 08, 2018: Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
Editas Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Editas Medicine Raises USD120 Million in Series B Financing 13
Editas Medicine Raises US$43 Million In Series A Financing 16
Editas Medicine Enters into Licensing and Option Agreement with Beam Therapeutics 18
Allergan and Editas Medicine Exercise of Options to Co-Develop EDIT-101 19
Adverum Biotechnologies Extends Agreement with Editas Medicine 20
Editas Medicine Enters into Agreement with Fondazione Telethon and Ospedale San Raffaele 21
Editas Medicine Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 22
Juno Therapeutics Enters into Research Agreement with Editas Medicine 23
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 26
Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 28
Editas Medicine Enters into Licensing Agreement with Duke University 29
Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 30
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 31
Editas Medicine Plans to Raise Funds through Public Offering of Securities 33
Editas Medicine Plans to Raise up to USD150 Million in Public Offering of Shares 34
Editas Medicine Raises USD57.5 Million in Public Offering of Shares 35
Editas Medicine Raises USD103.5 Million in Public Offering of Shares 37
Editas Medicine Raises USD108.6 Million in IPO 39
Editas Medicine Inc, Key Competitors 41
Editas Medicine Inc, Key Employees 42
Editas Medicine Inc, Subsidiaries 43
List of Figures
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10